Methodology and Problems of Protein‐Ligand Docking: Case Study of Dihydroorotate Dehydrogenase, Thymidine Kinase, and Phosphodiesterase 4

References

• Bissantz C., Folkers G., Rognan D. Protein‐Based Virtual Screening of Chemical Databases. 1. Evaluation of Different Docking/Scoring Combinations. J. Med. Chem. 2001; 43: 4759–4767
   Google Scholar
• Fairbanks L. D., Bofill M., Ruckemann K., Simmonds H. A. Importance of Ribonucleotide Availability to Proliferating T‐Lymphocytes from Healthy Humans. Disproportionate Expansion of Pyrimidine Pools and Contrasting Effects of De Novo Synthesis Inhibitors. J. Biol. Chem. 1995; 270: 29682–29689
   PubMed Web of Science ®Google Scholar
• Chen S. F., Perrella F. W., Behrens D. L., Papp L. M. Inhibition of Dihydroorotate Dehydrogenase Activity by Brequinar Sodium. Cancer Res. 1992; 52: 3521–3527
   PubMedGoogle Scholar
• Williamson R. A., Yea C. M., Robson P. A., Curnock A. P., Gadher S., Hambleton A. B., Woodward K., Bruneau J. M., Hambleton P., Moss D., et al. Dihydroorotate Dehydrogenase is a High Affinity Binding Protein for A77 1726 and Mediator of a Range of Biological Effects of the Immunomodulatory Compound. J. Biol. Chem. 1995; 270: 22467–22472
   PubMed Web of Science ®Google Scholar
• Williamson R. A., Yea C. M., Robson P. A., Curnock A. P., Gadher S., Hambleton A. B., Woodward K., Bruneau J. M., Hambleton P., Spinella‐Jaegle S., Morand P., Courtin O., Sautes C., Westwood R., Hercend T., Kuo E. A., Ruuth E. Dihydroorotate Dehydrogenase is a Target for the Biological Effects of Leflunomide. Transplant. Proc. 1996; 28: 3088–3091
   PubMedGoogle Scholar
• Culver K. W., Ram Z., Wallbridge S., Ishii H., Oldfield E. H., Blaese R. M. In Vivo Gene Transfer with Retroviral Vector‐Producer Cells for Treatment of Experimental Brain Tumors. Science 1992; 256: 1550–1552
   PubMed Web of Science ®Google Scholar
• Bonini C., Ferrari G., Verzeletti S., Servida P., Zappone E., Ruggieri L., Ponzoni M., Rossini S., Mavilio F., Traversari C., Bordignon C. HSVTK Gene Transfer Into Donor Lymphocytes for Control of Allogeneic Graft‐Versus‐Leukemia. Science 1997; 276: 1719–1724
   PubMed Web of Science ®Google Scholar
• Culver K. W., Van Gilder J., Link C. J., Carlstrom T., Buroker T., Yuh W., Koch K., Schabold K., Doornbas S., Wetjen B., et al. Gene Therapy for the Treatment of Malignant Brain Tumors with In Vivo Tumor Transduction with the Herpes Simplex Thymidine Kinase Gene/Ganciclovir System. Hum. Gene Ther. 1994; 5: 343–379
   PubMedGoogle Scholar
• Elion G. B., Furman P. A., Fyfe J. A., de Miranda P., Beauchamp L., Schaeffer H. J. Selectivity of Action of an Antiherpetic Agent, 9‐(2‐Hydroxyethoxymethyl) Guanine. Proc. Natl. Acad. Sci. USA 1977; 74: 5716–5720
   PubMed Web of Science ®Google Scholar
• Keller P. M., Fyfe J. A., Beauchamp L., Lubbers C. M., Furman P. A., Schaeffer H. J., Elion G. B. Enzymatic Phosphorylation of Acyclic Nucleoside Analogs and Correlations with Antiherpetic Activities. Biochem. Pharmacol. 1981; 30: 3071–3077
   PubMed Web of Science ®Google Scholar
• Wild K., Bohner T., Folkers G., Schulz G. E. The Structures of Thymidine Kinase from Herpes Simplex Virus Type 1 in Complex with Substrates and a Substrate Analogue. Protein Sci. 1997; 6: 2097–2106
   PubMed Web of Science ®Google Scholar
• Kussmann‐Gerber S., Kuonen O., Folkers G., Pilger B. D., Scapozza L. Drug Resistance of Herpes Simplex Virus Type 1–Structural Considerations at the Molecular Level of the Thymidine Kinase. Eur. J. Biochem. 1998; 255: 472–481
   PubMedGoogle Scholar
• Champness J. N., Bennett M. S., Wien F., Visse R., Summers W. C., Herdewijn P., de Clerq E., Ostrowski T., Jarvest R. L., Sanderson M. R. Exploring the Active Site of Herpes Simplex Virus Type‐1 Thymidine Kinase by X‐Ray Crystallography of Complexes with Aciclovir and Other Ligands. Proteins 1998; 32: 350–361
   PubMed Web of Science ®Google Scholar
• Bennett M. S., Wien F., Champness J. N., Batuwangala T., Rutherford T., Summers W. C., Sun H., Wright G., Sanderson M. R. Structure to 1.9 A Resolution of a Complex with Herpes Simplex Virus Type‐1 Thymidine Kinase of a Novel, Non‐Substrate Inhibitor: X‐Ray Crystallographic Comparison with Binding of Aciclovir. FEBS Lett. 1999; 443: 121–125
   PubMedGoogle Scholar
• Perozzo R., Jelesarov I., Bosshard H. R., Folkers G., Scapozza L. Compulsory Order of Substrate Binding to Herpes Simplex Virus Type 1 Thymidine Kinase. A Calorimetric Study. J. Biol. Chem. 2000; 275: 16139–16145
   PubMed Web of Science ®Google Scholar
• Prota A., Vogt J., Pilger B., Perozzo R., Wurth C., Marquez V. E., Russ P., Schulz G. E., Folkers G., Scapozza L. Kinetics and Crystal Structure of the Wild‐Type and the Engineered Y101F Mutant of Herpes Simplex Virus Type I Thymidine Kinase Interacting with (North)Methanocarba‐Thymidine. Biochemistry 2000; 39: 9597–9603
   PubMed Web of Science ®Google Scholar
• Livi G. P., Kmetz P., McHale M. M., Cieslinski L. B., Sathe G. M., Taylor D. P., Davis R. L., Torphy T. J., Balcarek J. M. Cloning and Expression of cDNA for a Human Low‐Km, Rolipram‐Sensitive Cyclic AMP Phosphodiesterase. Mol. Cell Biol. 1990; 10: 2678–2686
   PubMedGoogle Scholar
• Conti M., Jin S. L., Monaco L., Repaske D. R., Swinnen J. V. Hormonal Regulation of Cyclic Nucleotide Phosphodiesterases. Endocr. Rev. 1991; 12: 218–234
   PubMed Web of Science ®Google Scholar
• Teixeira M. M., Gristwood R. W., Cooper N., Hellewell P. G. Phosphodiesterase (PDE)4 Inhibitors: Anti‐Inflammatory Drugs of the Future?. Trends Pharmacol. Sci. 1997; 18: 164–171
   PubMed Web of Science ®Google Scholar
• Barnette M. S., Underwood D. C. New Phosphodiesterase Inhibitors as Therapeutics for the Treatment of Chronic Lung Disease. Curr. Opin. Pulm. Med. 2000; 6: 164–169
   PubMedGoogle Scholar
• Spina D. The Potential of PDE4 Inhibitors in Asthma or COPD. Curr. Opin. Investig. Drugs 2000; 1: 204–213
   PubMedGoogle Scholar
• http://www.rcsb.org, Accessed January 2002
   Google Scholar
• Rarey M., Kramer B., Lengauer T. Time‐Efficient Docking of Flexible Ligands into Active Sites of Proteins. Ismb 1995; 3: 300–308
   Google Scholar
• Kramer B., Rarey M., Lengauer T. Evaluation of the FLEXX Incremental Construction Algorithm for Protein‐Ligand Docking. Proteins 1999; 37: 228–241
   PubMed Web of Science ®Google Scholar
• Morris G. M., Goodsell D. S., Halliday R. S., Huey R., Hart W. E., Belew R. K., Olson A. J. Automated Docking Using a Lamarckian Genetic Algorithm and an Empirical Binding Free Energy Function. J. Comput. Chem. 1998; 19: 1639–1662
   Web of Science ®Google Scholar
• Oshiro C. M., Kuntz I. D., Dixon J. S. Flexible Ligand Docking Using a Genetic Algorithm. J. Comput. Aid. Mol. Des. 1995; 9: 113–130
   PubMed Web of Science ®Google Scholar
• www.library.wisc.edu/help/quickguide/acd.htm, (Accessed January 2002)
   Google Scholar
• www.tripos.com/software/cscore_print.html, (Accessed January 2002)
   Google Scholar
• Liu S., Neidhardt E. A., Grossman T. H., Ocain T., Clardy J. Structures of Human Dihydroorotate Dehydrogenase in Complex with Antiproliferative Agents. Struct. Fold. Des. 2000; 8: 25–33
   Google Scholar
• McLean J. E., Neidhardt E. A., Grossman T. H., Hedstrom L. Multiple Inhibitor Analysis of the Brequinar and Leflunomide Binding Sites on Human Dihydroorotate Dehydrogenase. Biochemistry 2001; 40: 2194–2200
   PubMed Web of Science ®Google Scholar
• Pospisil P., Scapozza L., Folkers G. The Role of Water in Drug Design: Thymidine Kinase as Case Study. Rational Approaches to Drug Design. 13th European Symposium on Quantitative Structure‐Activity Relationship, H.‐D. Höltje, W. Sippl. Prous Science, Barcelona‐Philadelphia 2001; 92–96
   Google Scholar
• Dym O., Xenarios I., Ke H., Colicelli J. Molecular Docking of Competitive Phosphodiesterase Inhibitors. Mol. Pharmacol. 2002; 61: 20–25
   PubMed Web of Science ®Google Scholar
• Xu R. X., Hassell A. M., Vanderwall D., Lambert M. H., Holmes W. D., Luther M. A., Rocque W. J., Milburn M. V., Zhao Y., Ke H., Nolte R. T. Atomic Structure of PDE4: Insights into Phosphodiesterase Mechanism and Specificity. Science 2000; 288: 1822–1825
   PubMed Web of Science ®Google Scholar
• Laliberte F., Han Y., Govindarajan A., Giroux A., Liu S., Bobechko B., Lario P., Bartlett A., Gorseth B., Gresser M., Huang Z. Conformational Difference Between PDE4 Apoenzyme and Holoenzyme. Biochemistry 2000; 39: 6449–6458
   PubMedGoogle Scholar
• Beese L. S., Steitz T. A. Structural Basis for the 3′‐5′ Exonuclease Activity of Escherichia Coli DNA Polymerase 1: A Two Metal Ion Mechanism. EMBO J. 1991; 10: 25–33
   PubMed Web of Science ®Google Scholar